Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

South Korean firm Celltrion announced that the European Commission (EC) has granted marketing authorization for Avtozma ...

Celltrion has secured marketing authorisation from the European Commission (EC) for Avtozma (CT-P47), a biosimilar to Chugai ...

Celltrion announced on the 24th that it has received product approval from the European Commission (EC) for ACTEMRA ...

Celltrion today announced that the European Commission (EC) has granted marketing authorization for Avtozma® (CT-P47), a ...

The Food and Drug Administration (FDA) has approved Avtozma ® (tocilizumab-anoh), a biosimilar to Actemra ® (tocilizumab), in both intravenous (IV) and subcutaneous (SC) formulations.

Over one third of patients with giant cell arteritis exhibit vascular inflammation even after receiving treatment with tocilizumab and glucocorticoids for at least 6 months, which suggests the ...

The US Food and Drug Administration (FDA) has approved Avtozma (tocilizumab-anoh) as a biosimilar of the original reference biologic tocilizumab (Actemra), according to a January 30 announcement ...

FDA approved another biosimilar to tocilizumab (Actemra), branded as Avtozma, for the intravenous or subcutaneous treatment of rheumatoid arthritis, COVID-19, and other tocilizumab-approved ...

As a biosimilar to Actemra, tocilizumab-anoh in both IV and SC formulation is approved to treat rheumatoid arthritis, pJIA, sJIA, COVID-19, and giant cell arteritis. The FDA recently approved ...